Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of CD71 Expression Following rEPO Administration
NCT04073849Phase 1Completed
- Sponsor
- Sports Medicine Research and Testing Laboratory
- Start
- Jul 2019
- Primary completion
- Nov 2020
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of epoetin alfa in anemia (2 arms), sponsored by Sports Medicine Research and Testing Laboratory. Primary endpoints: CD71 (transferrin receptor) concentration at 8 months, Hemoglobin concentration at 8 months and 3 more. Started Jul 2019; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT04073849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073849.